Has the Price of Wegovy Gone Down in the UK?

Has Wegovy gone down in price, or is that a misconception?

Prices for Wegovy in the UK private market have not come down as a trend. The reported private cost of semaglutide pens has generally held or edged upward since 2023, shaped partly by supply pressures and partly by the pricing decisions of manufacturers. Eli Lilly's move to roughly triple the UK list price of the highest-dose Mounjaro pen from around £122 to around £330 per four-week pen from September 2025 (as widely reported) did not cause Wegovy prices to drop; if anything it reset market expectations across the GLP-1 category.

The full picture of whether Wegovy has gone up in price is worth reading if you want the supply-chain context. The short version: genuine, licensed product running through the UK supply chain carries real costs, and those have not compressed. If you have seen prices that look dramatically lower than the broad private market range of roughly £149 to £375 per month depending on dose and provider, that gap is worth questioning.

There is one nuance. Individual providers price differently, and the launch of the new 7.2mg Wegovy pen, approved by the MHRA in April 2026, has added a higher-dose option rather than a cheaper entry point. The range has expanded; the floor has not dropped, and if you are curious about whether Wegovy did go down in price at any point, the evidence suggests it has not in any meaningful way. You can check whether any online pharmacy is legitimately registered in seconds using the GPhC pharmacy register — that is a useful 30-second habit before handing over any payment details.

What do headline prices typically leave out?

A quoted monthly price for Wegovy from any provider deserves scrutiny. The figure you see advertised may cover the pen only, leaving the consultation fee, the prescription charge, and delivery as separate line items billed at checkout or at renewal.

Some services also charge for dose-review appointments, for transfer assessments if you are moving from another provider, or for out-of-hours aftercare. None of that is inherently wrong, but it does mean a lower headline price can become comparable to or more expensive than a higher all-inclusive one once everything is added up. The annual cost of Wegovy is a more revealing comparison point than any single-pen figure.

NICE's recommendation for semaglutide (TA875) covers use within specialist NHS weight management services, for a maximum of two years, within a structured programme. NICE guidance TA875 sets the NHS eligibility criteria clearly; private providers operate outside that framework. Understanding what a legitimate private service includes helps you compare accurately rather than on price alone.

Where does nume sit on price, and why?

We are not the least expensive option on the market, and that is a deliberate choice. One transparent price covers the consultation, the prescription, the treatment, and next-working-day tracked delivery on every order. There are no separate fees layered in, no subscription you need to remember to cancel, and no auto-renewal. Every repeat order gets clinical re-review, a real prescriber, not automated software, reads your answers before anything ships.

The full breakdown of Wegovy pricing at nume explains what is covered. For context on how the market overall has moved, whether Wegovy's price is going down looks at the supply and demand forces shaping private costs, and for a forward-looking perspective you can read about whether Wegovy will go down in price as the market develops. Our clinical team reviews every case on its own merits; treatment pricing is shown on the consultation and treatment page, where you can also start your free consultation.

Why cheapest is the wrong question to ask about a prescription medicine

Wegovy is a prescription-only medicine. The MHRA has repeatedly warned about counterfeit weight-loss pens circulating online and through social media, seized under enforcement operations that removed around 20 million doses of illegally traded product with a street value of roughly £45 million in 2025 alone. Fake pens have contained insulin. The MHRA's Yellow Card scheme allows anyone to report a suspect seller or product, and that option exists because the risk is real.

A seller offering semaglutide without a prior clinical assessment is breaking UK law. A price that sits well below the private market range is far more likely to reflect that than any genuine efficiency saving. The right question is not which service is cheapest, but which service runs proper clinical oversight, sources from the licensed UK supply chain, and makes it easy for you to verify them. Those criteria answer themselves fairly quickly for anyone willing to spend a minute checking. You can read more about what to look for when choosing a provider on our Wegovy treatment page, or explore how it sits alongside other options on our weight-loss treatments overview.